NEW YORK–(BUSINESS WIRE)–Catalio Capital Management, LP (“Catalio”), a multi-strategy life sciences investment firm, today announced that Chau Khuong, who was formerly a partner at OrbiMed Advisors , joined the firm as a general partner and senior advisor. . Mr. Khuong will be based in New York and serve on the investment committees of Catalio’s flagship private equity strategy, Nexus, and its credit opportunities strategy.
Mr. Khuong previously spent nearly twenty years at OrbiMed Advisors, one of the world’s leading healthcare-focused investment firms, where he served as a member of the investment committee of the OrbiMed venture capital funds. Throughout his career, Mr. Khuong has led or co-led investments in more than two dozen life science companies, ultimately resulting in twelve FDA-approved drugs or therapeutic devices.
Co-founder and Managing Partner George Petrocheilos said, “At Catalio, we are building a highly differentiated portfolio of industry-leading companies led by the brightest minds in life sciences. The addition of Chau, who brings nearly two decades of experience as a senior venture capitalist building high-growth, early-stage biotechnology companies, reinforces our mission to bring to market innovative, game-changing and life-saving therapies. We are delighted to welcome him to Catalio. Co-Founder and Managing Partner Dr. Jacob Vogelstein added: “Chau’s unique skills as a seasoned and prolific investor, combined with extensive experience in finance, business development, company formation, IPOs and M&As, and the approvals process of the FDA, will be a real asset to our company, our investors and our portfolio companies.
Mr. Khuong said: “Building and growing emerging life science companies is my passion, and I am excited to apply my deep industry knowledge and expertise to the benefit of Catalio and its portfolio companies. Throughout my career, I’ve learned that success requires discipline, honest ideas, diverse perspectives, and a focus on relationships. George and Jacob share these principles and have a proven track record in identifying and managing great businesses. I am delighted to collaborate with them and other entrepreneurs to generate value and creativity. »
Mr. Khuong has served as a director or observer on the boards of numerous public and private companies, including Arius Research (acquired by Roche), Fusion Pharmaceuticals (NASDAQ: FUSN), Glaukos Medical (NYSE: GKOS), Intellia Pharmaceuticals ( NASDAQ: NTLA), Intercept Pharmaceuticals (NASDAQ: ICPT), Inspire Medical Systems (NYSE: INSP), NextCure (NASDAQ: NXTC), Noctrix, Pieris (NASDAQ: PIRS), Rempex (acquired by Medicines Company) and ReViral (announced acquisition by Pfizer). He earned a BS and MPH both from Yale University.
Catalio has been very active since its creation two years ago. Earlier this month, the company announced the successful closing of its third venture capital fund, Catalio Nexus Fund III, with over $381 million in total capital commitments, surpassing its initial target of $300 million. dollars. The company continues to add talent in all facets of the organization, which now has over 28 employees and has invested in 45 companies to date.
About Catalogo Capital Management
Catalio Capital Management, LP, is a multi-strategy life sciences investment firm focused on breakthrough biomedical technology companies developing the next generation of medicines, devices, diagnostics and information data-based. The Catalio partnership includes more than 36 world-renowned scientists with academic bona fide, who have each launched several successful companies based on their research. Catalio has offices in New York, Baltimore and London. For more information, visit www.cataliocapital.com.